AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00039871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REBETOL (ribavirin; SCH 18908)
Description: REBETOL (ribavirin) administered on a weight basis: 800-1400 mg/day orally (PO) for up to 48 weeks
Study NCT03049293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: The impact of Midazolam levels in follicular fluid.
Study NCT01490723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 250 mg/m2 by vein preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively on Days -22 and -14.
Study NCT01490723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111In Ibritumomab
Description: (5.0 mCi +/- 10% of 111In) by vein immediately following the infusion of rituximab on Day -22.
Study NCT01490723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planar Scintigraphy Imaging
Description: Day -22, -21 to -16: Planar scintigraphy whole-body imaging started on Day -22 post 111In Ibritumomab infusion prior to voiding, and repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Whole-body planar scintigraphy imaging will be repeated between 22-26 hours, then between 70-74 hours, and later between 142-146 hours post 111In Ibritumomab injection.
Study NCT01490723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y IbritumomabTiuxetan
Description: Calculated to deliver not below 10 Gy to normal organs (liver, lungs, kidneys) by vein post rituximab on Day -14.
Study NCT01490723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 intravenously on Days -5, -4, and -3.
Study NCT01490723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 130 mg/m2 intravenously on D-5, -4 and -3.
Study NCT01490723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 1 mg/kg (based on actual body weight) on Days -2 and -1 will be administrated to patients receiving a cord blood (CB) and a matched unrelated donor (MUD).
Study NCT01490723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no Graft versus Host Disease (GVHD) is present.~For patients receiving cord blood (CB) graft, the Graft versus Host Disease (GvHD) prophylaxis will be with Tacrolimus. Tacrolimus will start on D-2 administrated at starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on D -2 and will be tapered around Day +180 if no GvHD is present.
Study NCT01490723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 by vein on Day +1, +3 and +6. Patients receiving an unrelated graft will also be given methotrexate on Day +11 after the transplant.
Study NCT01490723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate
Description: 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth administered from Days -3 to +45 and then tapered to end by day 100 if there is no Graft versus Host Disease (GVHD).
Study NCT01490723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously beginning Day +7 for patients receiving related and matched unrelated donor (MUD) grafts and on Day 0 for patients receiving a cord blood (CB). G-CSF will continue until the absolute neutrophil count (ANC) is > 500 \* 10/L for 3 consecutive days.
Study NCT01490723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Stem Cell Transplantation on Day 0
Study NCT04512339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Dupilumab injections (blinded labels)
Study NCT04512339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections (blinded labels), matching the dupilumab injections in quantity and appearance
Study NCT03031847 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac Resynchronization Therapy Pacemaker
Description: Patients randomized to the pacemaker arm will receive a CRT-P device.
Study NCT03031847 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac Resynchronization Therapy Defibrillator
Description: Patients randomized to the defibrillator arm will receive a CRT-D device.
Study NCT03598101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TONEFITreha
Description: The newly developed Tonefit Reha is based on the existing fitness device, the TONEFIT belt. Similar to Nordic Walking, the device aims to include upper limb activity in walking exercise to train the shoulder girdle and arm. While Nordic Walking uses poles, the existing TONEFIT belt uses body-worn resistance handles to actively involve the upper body. It is worn around the waist, like a belt. The two independent pull-push elements with non-adjustable resistance on each side allow increased intensity for strengthening and endurance training during walking, particular for upper extremities and trunk stability.
Study NCT05050071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allium Sativum
Description: Sixty-six permanent mature necrotic incisors associated with apical periodontitis in male children were selected. Teeth were randomly divided into three groups (n=22) according to intra canal medications used; group I: Ca OH2, group II: garlic extract and group III: mixture of Ca OH2 and garlic extract. After access preparation, four microbiological samples (S) were as follows; (S1): were taken before canal instrumentation and irrigation. (S2): after cleaning and shaping, Then, the third samples (S3) and forth samples (S4) were taken after placement of the tested intracanal medications into the corresponding canals, for 7 and 14 days respectively. Total DNA was extracted from microbiological samples and relative quantitive real time PCR reactions were done to quantify the relative gene expression levels (FC) for Streptococcus and Enterococcus faecalis species.
Study NCT05050071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allium Sativum
Description: Sixty-six permanent mature necrotic incisors associated with apical periodontitis in male children were selected. Teeth were randomly divided into three groups (n=22) according to intra canal medications used; group I: Ca OH2, group II: garlic extract and group III: mixture of Ca OH2 and garlic extract. After access preparation, four microbiological samples (S) were as follows; (S1): were taken before canal instrumentation and irrigation. (S2): after cleaning and shaping, Then, the third samples (S3) and forth samples (S4) were taken after placement of the tested intracanal medications into the corresponding canals, for 7 and 14 days respectively. Total DNA was extracted from microbiological samples and relative quantitive real time PCR reactions were done to quantify the relative gene expression levels (FC) for Streptococcus and Enterococcus faecalis species.
Study NCT05050071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction
Description: Change in the bacterial load in response to different treatment procedures
Study NCT05050071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polymerase chain reaction
Description: Change in the bacterial load in response to different treatment procedures
Study NCT04461925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: per os
Study NCT04461925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: per os
Study NCT04461925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormones
Description: a moderate amount of dexamethasone i/v
Study NCT04461925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormones
Description: a moderate amount of dexamethasone i/v
Study NCT04461925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant Therapy
Description: Sub-Q
Study NCT04461925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulant Therapy
Description: Sub-Q
Study NCT04438655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antibiotic drugs
Description: Oral antibiotic drugs:~- Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon.
Study NCT04438655 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Parenteral prophylaxis
Description: Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg.
Study NCT04438655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral prophylaxis
Description: Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg.
Study NCT02140125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2408
Description: subcutaneous administration
Study NCT00633594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: DL 1, DL 2, and DL 3: 375 mg/m2 IV Days 1, 8, and 15; Cycles 2-6: 375 mg/m2 IV Day 1~Same for DL-1.
Study NCT00633594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: DL 1, DL 2, and DL 3: 1.3 mg/m2 IV Days 1, 4, 8, and 11~Same for DL-1.
Study NCT00633594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: DL 1: 15 mg PO daily Days 1-14 followed by 7 days of rest~DL 2: 20 mg PO daily Days 1-14 followed by 7 days of rest~DL 3: 25 mg PO daily Days 1-14 followed by 7 days of rest~DL-1: 10 mg PO daily Days 1-14 followed by 7 days of rest
Study NCT02140125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous administration
Study NCT00061321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine and mulitvitamins
Description: Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum Infants (Arm 2 Only): Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
Study NCT00061321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine and mulitvitamins
Description: Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum Infants (Arm 2 Only): Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
Study NCT03121443 — intervention group
Intervention type: OTHER
Intervention: Perfusion index
Description: supine,prone, trendelenburg,reverse trendelenburg,45 degrees back up sitting position, 45 degrees legs lifted supine position.
Study NCT01583127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Behavioral Interventions & Supports
Description: Implementation of the School-Wide Positive Behavioral Interventions and Supports model across 4 school years.
Study NCT01527006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perampanel
Description: During the titration period, participants started at a set daily dose of 0.015 mg/kg and had doses up-titrated at 1-week intervals (6 titration steps) to a maximum daily dose of 0.18 mg/kg. During the Maintenance Period, participants continued taking perampanel oral suspension once daily at the dose level they achieved at the end of the Titration Period. During the extension phase, participants continued taking perampanel oral suspension once daily, at the dose level achieved at the end of the treatment phase of the core study to a maximum daily dose of 0.18 mg/kg. The maximum total daily dose a participant was allowed was 12 mg.
Study NCT00836667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoloft® 100 mg Tablets
Description: 1 x 100 mg, single-dose fed
Study NCT00836667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride 100 mg Tablets
Description: 1 x 100 mg, single-dose fed
Study NCT04551976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Pay attention to the present moment, on purpose, in a nonjudgemental way.
Study NCT01854463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2000IU per day
Study NCT01854463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: elemental calcium 200mg per day per 24 weeks
Study NCT04596007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC83518 tablets
Description: Each dose of HEC83518 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
Study NCT04596007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04461925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Оxygen therapy
Description: Оxygen therapy, mechanical ventilation and other supportive therapies
Study NCT04461925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Оxygen therapy
Description: Оxygen therapy, mechanical ventilation and other supportive therapies
Study NCT00752973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MALG (malathion) Treatment
Description: MALG applied for 30 minutes
Study NCT02392533 — intervention group
Intervention type: OTHER
Intervention: Education
Description: Education
Study NCT03774095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydrolyzed pine nut oil
Description: Given 30 min prior to oral glucose tolerance test
Study NCT03911258 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nasopharyngeal swab versus nasal wash
Description: The type of procedure will be determine according to patient collaboration
Study NCT03483194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Bliss is a 3D Interactive application designed to meet the needs of escape and relaxation of people in isolation and / or stress and / or during painful care here osteo-medullary biopsy
Study NCT00853385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP 690,550
Description: tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months
Study NCT00853385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months
Study NCT00853385 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets BID PO advance to 5mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
Study NCT00853385 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets BID PO advance tablets to10mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
Study NCT00853385 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biologic TNFi
Description: placebo tablets BID PO plus adalimumab 40 mg q2 week SC injections for 12 months
Study NCT02799381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized antiparkinsonian treatment
Description: Dose levels of prescribed antiparkinsonian medications were individually optimized to their maximum therapeutic effect.
Study NCT02799381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-Carbidopa Intestinal Gel (LCIG)
Description: Dose levels were individually optimized.
Study NCT01001104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
Study NCT02799381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Legacy ambulatory infusion pump
Description: (manufactured by Smiths Medical)
Study NCT02799381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy tube
Description: (PEG tube)
Study NCT01001104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by SC injection, QW for 12 weeks.
Study NCT00820300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost-PPDS
Description: Control of IOP compared to baseline for the experimental doses of Latanoprost-PPDS for 4 months or until loss of efficacy.
Study NCT05316870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions
Description: Compared with the current anticoagulation management service, we pay more attention to early initiation of anticoagulant therapy and long-term follow-up management.
Study NCT05316870 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional general practitioner management model
Description: The current general practitioner anticoagulation management model was continued in the control group.
Study NCT01860508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed /carboplatin
Study NCT04530851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS
Description: * Counseling~* H2- antagonist and metroclopramide for prevent aspiration~* Drink clear liquid until 2 hour before surgery~* First generation cephalosporin in 60 minute before surgery~* Clorhexidine for skin cleansing and Povidine for vaginal cleansing~* Regional anesthesia~* Keep warming~* Blunt expansion of uterine incision~* Do not peritoneal suture and subcuticular suture if less than 2 cm~* Local wound anesthesia.~* Paracetamol and NSAIDs for for pain control~* Early remove catheter and ambulation~* 5-HT3 antagonist for prevent nausea
Study NCT02799381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jejunal extension tube
Description: (J-tube)
Study NCT03195101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transconjunctival orbitotomy approach
Description: approach the orbital tumor through an incision in the conjunctiva, This is followed by blunt dissection of the tenons capsule. A traction suture is applied over the corresponding rectus muscle to guide the globe toward the desired direction. The orbital fat is retracted by malleable retractor and blunt dissection through the orbital connective tissue continues until reaching the edge of the tumor. After the mass is exposed, a biopsy or complete resection of the mass is taken place
Study NCT03368859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenous
Study NCT03368859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Intravenous
Study NCT03368859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil - bolus
Description: Intravenous
Study NCT03774095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydrolyzed pine nut oil and olive oil
Description: Given 30 min prior to oral glucose tolerance test
Study NCT02954042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvital probe
Description: Pelvital probe
Study NCT02954042 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Probe
Description: Placebo Probe
Study NCT03893344 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: detection of STAT4 gene
Description: Individuals within both groups will be subjected to STAT4 gene polymorphism typing using both PCR and flow cytometry from a peripheral blood sample
Study NCT02829944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT02829944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Study NCT02829944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01018446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
Study NCT01556347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis
Study NCT00959374 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V-Loc 180/90 Wound Closure Device
Description: Barbed absorbable suture
Study NCT00959374 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3-0 Monocryl Absorbable Sutures
Description: 3-0 Monocryl Absorbable Suture (non-barbed)
Study NCT00641927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: 37.5 mg - 375 mg daily, 12 Weeks
Study NCT00641927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Carbonate
Description: 300 mg - 2100 mg daily, 12 weeks
Study NCT02708082 — intervention group
Intervention type: DEVICE
Intervention: OCT scanning and HFA perimetry
Description: Imaging of the optic nerve and nerve fiber layer / measurement of visual field
Study NCT02713256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: CFZ533 intravenously over approximately one hour
Study NCT03102840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: Nasopharyngeal swab will be performed in all participants